On April 28, 2026, the DEA’s Final Order rescheduling state-licensed marijuana from Schedule I to Schedule III took effect. Seventeen days later, on May 15, 2026, ODAPC and the DOT Office of General Counsel posted a Part 40 Q&A clarifying that nothing changed for CDL drivers. A state medical marijuana card, a physician’s recommendation, and dispensary documentation are still not a “legitimate medical explanation” under §40.137. The MRO has no authority to verify a marijuana positive as negative on those grounds. Drivers who test positive will go through the SAP return-to-duty process. Here’s the regulatory logic, the operational impact, and what this means for the people in your testing program.

What changed on April 28

The DEA’s Final Order, published as 91 FR 22714 (AG Order 6754-2026, signed April 23, 2026), moved marijuana from Schedule I to Schedule III under the Controlled Substances Act. The order applies to FDA-approved marijuana-derived drug products and to state-regulated marijuana. The legal effect of rescheduling is significant in some contexts: Schedule III substances can be prescribed by a DEA-registered practitioner, are subject to less stringent record-keeping than Schedule I or II, and trigger different penalties under federal drug law.

A reasonable person reading the headlines could have concluded: if marijuana is now Schedule III, and Schedule III drugs can be prescribed, then a doctor’s recommendation should now satisfy the “legitimate medical explanation” standard under Part 40. That conclusion is wrong, and ODAPC moved quickly to say so.

What ODAPC said on May 15

On May 15, 2026, the DOT’s Office of Drug and Alcohol Policy and Compliance, jointly with the DOT Office of General Counsel, posted a new Q&A under 49 CFR §40.137. The core points are direct. State-dispensed marijuana is not an FDA-approved drug: even after rescheduling, the marijuana products sold at state-regulated dispensaries have not gone through the FDA’s drug approval process, and FDA approval is the gating step for a “prescribed” controlled substance under federal law. Without FDA approval, a controlled substance cannot be “prescribed” under federal law — a state physician’s “recommendation” or “certification” is a state-law construct, not a federal prescription, and the DEA’s rescheduling did not change the federal prescription requirements. Therefore, state medical marijuana documentation does not satisfy the §40.137(a) “legitimate medical explanation” requirement: a state medical marijuana card, a physician’s recommendation or certification, and dispensary records or receipts — none of those documents meets the federal standard. The MRO has no authority to verify a positive marijuana result as negative based on any of those documents; the MRO’s verification authority under §§40.137(a), 40.141, and 40.151 is unchanged, and a laboratory-confirmed marijuana positive will be verified as a positive result, with the driver reported to the Clearinghouse. The Q&A also reinforces what has been true since 2009: there is no medical-use exemption for DOT-regulated drivers, even in states that have legalized medical or recreational marijuana.

What this means for drivers

If you are a CDL driver subject to DOT drug testing — and any driver operating a CMV requiring a CDL is subject to Part 382 testing — the bottom line is unchanged. Marijuana is prohibited at all times: on duty, off duty, in any state, in any form. Federal law applies to you because you operate a CMV in interstate commerce, regardless of what state you live in or which state’s medical marijuana program you participate in. A state medical marijuana card does not protect you from a positive test; if you test positive, the MRO will verify the result based on the laboratory’s report, and your state card, your physician’s certification, and your dispensary purchase records have no force in the MRO process.

Any positive test or refusal triggers the full Clearinghouse process: immediate removal from safety-sensitive function, and reporting to the FMCSA Clearinghouse, which puts the driver in “prohibited” status. Under the Clearinghouse-II Final Rule (86 FR 55718), since November 18, 2024, your State Driver Licensing Agency will downgrade your CDL automatically. To restore your CDL, you must complete the SAP return-to-duty process: evaluation, education or treatment, a negative return-to-duty test under direct observation, and a follow-up testing plan that can extend up to five years. CBD products carry the same risk — many CBD products, including ones labeled “THC-free,” contain enough THC to produce a positive DOT drug test, the MRO cannot verify a CBD-related positive as negative, and the driver bears the risk of what is in any cannabinoid product they consume.

What this means for DERs and MROs

The May 15 Q&A doesn’t create new responsibilities for DERs or MROs — it reinforces existing ones. For MROs, verification of a laboratory-confirmed marijuana positive proceeds under §40.137(a); the driver may attempt to explain the positive with state medical marijuana documentation, but per the May 15 Q&A that documentation cannot satisfy the “legitimate medical explanation” standard, so the result is verified as positive, and the driver retains the unchanged right to request a split-specimen retest under §40.171. For DERs, when a driver presents state marijuana documentation — before testing, after testing, or after a Clearinghouse report — the response is the same: advise the driver that state marijuana documentation is not acceptable under DOT testing rules and proceed with the violation reporting and SAP referral process. For supervisors, §382.603 reasonable-suspicion training applies in the usual way; if you observe signs of marijuana impairment in a CDL driver, you order a reasonable-suspicion test based on your articulable observations, and the driver’s state medical marijuana documentation is not relevant to your decision to test.

The bigger picture

The DEA rescheduling is a significant event in federal drug policy. It changes how marijuana is regulated for some federal purposes, including research, taxation, criminal sentencing, and banking compliance, and it will likely change again in coming years as federal marijuana policy continues to evolve. For DOT-regulated drivers and the people who manage their testing programs, the practical answer is simpler than the policy debate suggests. The Department of Transportation regulates safety-sensitive work in transportation, and that regulation is grounded in the operational fact that THC impairs performance and is detectable in body fluids. That fact has not changed. Until and unless Congress amends the relevant statutes or the FDA approves a marijuana product for the kind of use a CDL driver would invoke, the answer for drivers will remain: no medical exemption, no MRO carve-out, no state-card pathway.

DotMotusCompliance Inc. is a private compliance services firm. We are not a government agency or a law firm. Always verify current rules with FMCSA and your state DMV before making employment decisions.